Du Youwen, Pan Linxin, Zhang Wenchen, Wei Shuangbiao, Fan Xu, Zhang Na, Wei Pengjun, Chen Xiaoqian, Qiao Zhi, Xie Li
School of Life Sciences, Anhui Medical University, Hefei, Anhui, China.
Department of Microbiology, Nanjing Medical University, Nanjing, Jiangsu, China.
Curr Cancer Drug Targets. 2025;25(2):131-143. doi: 10.2174/0115680096332450240827070033.
Hepatocellular carcinoma (HCC) is a global health problem with increasing morbidity and mortality, and exploring the diagnosis and treatment of HCC at the gene level has become a research hotspot in recent years. As the rate-limiting enzyme of carnosine hydrolysis, CNDP1 participates in the progress of many diseases, but its function in HCC has not been fully elucidated.
This study firstly screened differentially expressed genes from the biochip related to HCC by bioinformatic analysis, and CNDP1 was finally selected for in-depth study. Then the bioinformatics analysis results were validated by detecting the expression of CNDP1 in human HCC samples and hepatoma cell lines. Furthermore, the effect of CNDP1 on the malignant behavior of hepatoma cell lines were assessed using MTT colorimetric assay, EdU staining assay, colony formation, wound-healing assay and transwell, and the molecular mechanism was also preliminarily explored.
This study found that CNDP1 expression was decreased significantly in human HCC tissues and cell lines, and its overexpression could significantly suppress cell proliferation, migration and invasion of hepatoma cell lines. Mechanistically the GeneMANIA database predicted that CNDP1 could interact with various proteins involved in regulating PI3K-AKT-mTOR signaling pathway. Furthermore, this study showed that CNDP1 overexpression could effectively inhibit the activation of PI3KAKT- mTOR signaling pathways, more significantly, inhibition of PI3K-AKT-mTOR signaling pathway could disrupt the anti-cancer effect of CNDP1 on HCC.
This study confirm that CNDP1 expression is decreased significantly in HCC, and has potential anti-cancer activity, this discovery provides a cytological basis for further understanding the biological function of CNDP1 and diagnosis and gene therapy of HCC in the future.
肝细胞癌(HCC)是一个全球性的健康问题,其发病率和死亡率不断上升,近年来在基因水平上探索HCC的诊断和治疗已成为研究热点。作为肌肽水解的限速酶,CNDP1参与多种疾病的进展,但其在HCC中的功能尚未完全阐明。
本研究首先通过生物信息学分析从与HCC相关的生物芯片中筛选差异表达基因,最终选择CNDP1进行深入研究。然后通过检测CNDP1在人HCC样本和肝癌细胞系中的表达来验证生物信息学分析结果。此外,使用MTT比色法、EdU染色法、集落形成、伤口愈合试验和transwell评估CNDP1对肝癌细胞系恶性行为的影响,并初步探索其分子机制。
本研究发现CNDP1在人HCC组织和细胞系中的表达显著降低,其过表达可显著抑制肝癌细胞系的细胞增殖、迁移和侵袭。机制上,GeneMANIA数据库预测CNDP1可与参与调节PI3K-AKT-mTOR信号通路的多种蛋白质相互作用。此外,本研究表明CNDP1过表达可有效抑制PI3KAKT- mTOR信号通路的激活,更重要的是,抑制PI3K-AKT-mTOR信号通路可破坏CNDP1对HCC的抗癌作用。
本研究证实CNDP1在HCC中的表达显著降低,并具有潜在的抗癌活性,这一发现为进一步了解CNDP1的生物学功能以及未来HCC的诊断和基因治疗提供了细胞学基础。